Contribution. He developed the first widely used polio vaccine. It used "killed" poliovirus. The virus was inactivated with formaldehyde so that it could not cause disease. But it still prompted the body to make protective antibodies (Science History Institute).
At a glance
Item
Detail
Dates
1914-1995
Field
Medicine and public health
Case type
Pioneer
Discrimination or exclusion
No
Factor coverage
Favorable entries (helped or barrier absent) and adverse entries (barrier or not overcome) by factor. Factor tags are this site's classification.
An immigrant family. He was born in New York. By his own account, his mother came from Russia in 1901 with no schooling. He also said that his father designed ladies' neckwear in the garment industry and had only an elementary school education, and that his generation was the first in the family to go to college (Academy of Achievement). Sources differ on whether his father was also an immigrant (Salk Institute) or the son of Jewish immigrants (Science History Institute). None of the sources checked describes the family's income.
Admission quotas. A 2018 essay draws on Charlotte DeCroes Jacobs's biography. It states that unofficial quotas limited Jewish admission to most medical schools. It says Salk was rejected nearly everywhere he applied, and that only New York University offered him a place (The New Atlantis). This is a single secondary account.
Rejected for research posts. He did his internship at Mount Sinai Hospital. After that, several prestigious university hospitals and research institutes turned him down. The same essay says this was because of a preference for "Ivy League gentiles."
Skepticism of peers. Most virologists, including Albert Sabin, believed that only a live, weakened virus could give lasting immunity. In 1950 the polio typing committee rejected the method changes he proposed. Before the 1954 trial, Sabin argued to the American Medical Association and to Congress that a killed-virus vaccine was neither effective nor safe.
The Cutter incident. In April 1955 more than 200,000 children in five Western and Midwestern states got vaccine from Cutter Laboratories. In this vaccine the virus had not been fully inactivated. It caused 40,000 cases of polio. It left 200 children with some paralysis and killed 10 (Journal of the Royal Society of Medicine). Paul Offit's history of the incident clears Salk of blame. It puts the main responsibility on the federal regulator. But the incident fed calls by Sabin and others to stop using his vaccine.
Free public education. He went to Townsend Harris Hall, a selective public high school in Manhattan, and finished at 15 (The New Atlantis, Science History Institute). He then went to City College of New York and graduated with a science degree in 1933. He entered NYU's medical school at 19.
A mentor. Thomas Francis Jr. trained him at NYU on inactivated influenza vaccines. When other positions turned him down, Salk went back to Francis. In 1942 he joined him at the University of Michigan on a National Research Council fellowship. There, with U.S. Army support, they developed a killed-virus flu vaccine.
His own laboratory. In 1947 the University of Pittsburgh made him director of a new Virus Research Laboratory. The National Foundation for Infantile Paralysis gave him a first-year grant of nearly $150,000. He joined its project to type polioviruses. By 1951 that project confirmed three virus types.
Others' discoveries. In 1949 Enders, Weller, and Robbins grew poliovirus in tissue culture of non-nerve tissue. This let Salk grow large amounts of all three types in monkey kidney cells.
A team. His Pittsburgh staff included Julius Youngner, Byron Bennett, and L. James Lewis. Three others joined later. Youngner developed ways to grow the virus in monkey kidney cells. He also made a color test to measure antibodies (Boston Globe).
Public donations. President Roosevelt announced the National Foundation for Infantile Paralysis in September 1937. It was incorporated on January 3, 1938. It paid for the research and trials with private donations through its March of Dimes campaign. Eddie Cantor coined that name in November 1937. It became the organization's formal name only in 1979 (March of Dimes).
Mass participation and an independent evaluation. Volunteers ran the 1954 trial. Francis directed it, not Salk. The 1955 report counted 1,829,916 children in the study areas. This included observed controls who got no injection (University of Michigan School of Public Health). Other accounts give from 1 million to almost 2 million because they count different groups. Jacobs's biography, as summarized by Valiunas (2018), puts those who got the vaccine at over 600,000. In April 1955 the vaccine was reported safe and 80 to 90% effective against paralytic polio.
He was very famous with the public. Even so, he was never elected to the National Academy of Sciences, which admitted Sabin, Francis, Enders, and David Bodian (KQED, The New Atlantis). He never received a Nobel Prize. In the 1960s Sabin's oral live-virus vaccine replaced his in the United States.
Credit and patents. Some colleagues criticized Salk for not crediting the researchers his work built on. Members of his own team said he failed to single them out in his April 12, 1955, announcement speech. A United Press report at the time quoted him crediting six staff members. The printed text was headed "From the Staff of the Virus Research Laboratory." But Youngner confronted Salk about the speech in 1993. Salk did not patent the vaccine. Edward R. Murrow asked him who owned the patent on his television program See It Now. This was on April 12, 1955, the day the trial results were announced (The New Atlantis, Smithsonian Magazine, Slate). He answered, "Well, the people, I would say. There is no patent. Could you patent the sun?" (History of Vaccines). The historian Jane S. Smith found documents in the National Foundation's archives, as reported by Slate. According to them, the Foundation's lawyers had looked at whether the vaccine could be patented. They concluded that it did not meet the novelty requirement (Slate). A History.com account says instead that the lawyers did not pursue a patent in part because of Salk's reluctance (History.com). Smith's book was not opened for this document.
Pattern summary
Element
In this case
Door-opener
Francis
Knowledge source
Free public college, NYU, training under Francis
Institutional support
March of Dimes, University of Pittsburgh
Built on recent work
Enders, Weller, Robbins
Setback overcome
Rejections, peer skepticism, Cutter incident
Barrier not overcome
Credit disputes, never elected to the National Academy of Sciences
Also relevant: Bell, A., Chetty, R., Jaravel, X., Petkova, N., & Van Reenen, J. (2019). Who becomes an inventor in America? Quarterly Journal of Economics, 134(2), 647-713. All references